Is WHWK or XCUR more undervalued in 2026?

CirclFi compares Whitehawk Therapeutics, Inc. (WHWK) and Exicure, Inc. (XCUR) using 13 institutional-grade valuation models. WHWK has a Quality of Company score of 5.3/10 while XCUR scores 4.3/10.

Which is a better buy — WHWK or XCUR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do WHWK and XCUR valuations compare?

WHWK at $4.78 and XCUR at $2.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

WHWK vs XCUR Valuation Comparison 2026 — Intrinsic Value Analysis

WHWK

Biotechnology

Whitehawk Therapeutics, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$4.78

Last close

Models

12/13

Active

XCUR

Biotechnology

Exicure, Inc.

Quality

4.3

out of 10

Value Trap

DANGER

Price

$2.97

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	WHWK Fair Value	WHWK Upside	XCUR Fair Value	XCUR Upside
Bayesian DCF	Intrinsic	$1.66	-65.2%	$1.16	-60.8%
Earnings Power Value	Intrinsic	$1.26	-68.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.02	-36.9%	$0.08	-97.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for WHWK vs XCUR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

WHWK vs XCUR — Which Stock Is More Undervalued?

WHWK scores higher with a 5.3/10 quality rating vs XCUR's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Whitehawk Therapeutics, Inc. (WHWK) and Exicure, Inc. (XCUR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

WHWK currently trades at $4.78 with a QOC of 5.3/10, while XCUR trades at $2.97 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).